India's Strides Pharma approves demerger of CDMO business into Stelis Biopharma
25/09/2023 11:05
BENGALURU, Sept 25 (Reuters) - India's Strides Pharma Science SRID.NS on Monday said it approved the demerger of its contract development and manufacturing organisation and soft gelatin business to Stelis Biopharma. (Reporting by Kashish Tandon in Bengaluru; Editing by Dhanya Ann Thoppil) ((Kashish.Tandon@thomsonreuters.com;))
Recent news on Strides Pharma Science
See all newsIndia's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Brief: Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Brief: Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Brief: Strides Pharma Science March-Quarter Consol Net Profit 1.27 Billion Rupees